Legal and ethical issues in embryonic stem cell research Edward B. Goldman, JD Presented at the 6th Annual Prechter Lecture - "Stem Cells and Ethics" November 12, 2012 prechterfund.orgFrom:DepressionCenterViews:0 0ratingsTime:30:32More inScience Technology See more here: Legal and ethical issues in embryonic stem cell research - Video … Continue reading →

The Future Direction of Stem Cell Research - a trailer The award-winning documentary filmmaker, Dr. Elliott Haimoff of Global Science Productions, presents this trailer to direct the attention of the viewing public worldwide as to the future benefits that stem cell research has to offer. Dr. Haimoff hopes to produce a one-hour TV documentary special that would be a'sequel' to his pioneering programs "Playing God: Human Cloning" that was produced 11 years ago and received high acclaims and awards. This one-hour, high-definition, TV documentary special will introduce viewers to the amazing discoveries and applications that stem cell research will benefit humanity and take us beyond our wildest dreams....From:GlobalScienceProdsViews:0 0ratingsTime:04:16More inEducation Read this article: The Future Direction of Stem Cell Research - a trailer - Video … Continue reading →

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the World Stem Cell Summit 2012 in West Palm Beach, Florida on Tuesday, December 4, 2012. Dr. West will be presenting in the session on Developing Combination Products: Cells, Genes, and Devices at 1:30 pm EST which will include an update on product development, including Renevia, PanC-Dx, and OpRegen. The presentation will be made available on BioTime's website at http://www.biotimeinc.com. World Stem Cell Summit 2012 will be the 8th annual event produced by the Genetics Policy Institute (GPI), a non-profit organization. Planned by and for the stem cell and regenerative medicine community, the goal of the Summit is to accelerate the discovery and development of lifesaving cures and therapies. This year, panels will address advancing treatments for specific diseases and conditions including: cancer, diabetes, HIV/AIDS, cardiovascular disease, spinal cord injury, paralysis, multiple sclerosis, ALS, Parkinson's, eye diseases and others. About BioTime, Inc. BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem … Continue reading →

NEWARK, Calif., Nov. 29, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) announced today that Ann Tsukamoto, Ph.D., Executive Vice President, Research and Development, will make a presentation on the Company's clinical development programs at the 2012 World Stem Cell Summit to be held December 3-5 at the Palm Beach County Convention Center, West Palm Beach, Florida. Dr. Tsukamoto is scheduled to speak during the Clinical Trial Update session to be held 10:30 a.m. to 12:00 p.m. Eastern Time on Tuesday, December 4. Dr. Tsukamoto also will be moderating a discussion on the topic "Unproven Stem Cell Therapies and Deceptive Claims: Hidden Dangers to Patients." This plenary discussion is scheduled to be held 9:00 to 10:00 a.m. Eastern Time on Tuesday, December 4. StemCells, Inc. is a Silver Sponsor of the 2012 World Stem Cell Summit, which is planned by and for the global stem cell and regenerative medicine community and is the largest interdisciplinary stem cell conference. The goal of the 2012 World Stem Cell Summit is to accelerate the discovery and development of lifesaving cures and therapies by bringing together a range of stakeholders to establish a supportive environment of regulation, legislation, financing, reimbursement and patient advocacy. StemCells, Inc. … Continue reading →

Should patents on the products of embryonic stem cell research be allowed? The European Court of Justice said no, but the question has remained unanswered in Germany - until now. The German constitution, called the Basic Law, guarantees freedom of research. It also guarantees every human being the right to life. These two principles come into conflict when faced with the matter of human stem cell research. At least, they do if you take the view that life begins at conception rather than birth, because research is done using early-stage embryos, or more specifically the stem cells extracted from them. The embryos die during this process - though technology is being developed to prevent this. The German parliament, the Bundestag, has introduced a law that places strict limits on this research. For instance, scientists can only use stem cell lines that were imported before May 1, 2007, a restriction meant to hinder the production of stem cells, and therefore the death of embryos, as a result of demand from Germany. Patent rows Some German scientists want to patent the results and developments they have invented through their stem cell research, and the Federal Court of Justice (BGH) pronounced a verdict … Continue reading →

Stem cell banks could serve as a valuable resource for emerging treatments in the field of regenerative medicine, though challenges remain to making them a reality, according to a panel of international experts who gathered at UCSF for a stem cell conference last month. Funding for the development of stem cell lines for research has long been subject to debate, especially before President Barack Obama lifted a Bush-era ban on federal funding in 2009, but now scientists are discussing how to best meet the anticipated need for stem cells for medicine as well as research. Shinya Yamanaka, MD, PhD Stem cell treatments developed from adult cells rather than from embryonic tissue are expected to enter clinical trials for macular degeneration in Japan next year, and early successes in such trials aimed at replacing damaged tissues would be expected to drive demand for such stem cells upward. Worldwide, stem cell scientists in academia, government and the private sector are gauging strategies for moving forward with stem cell banks to meet expected demand. So far, countries have been taking different paths toward acquiring these resources, panelists said at an Oct. 25 discussion at the International Society for Stem Cell Research conference held … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Dublin - Research and Markets has announced the addition of the "Frontiers In Pluripotent Stem Cells Research And Therapeutic Potentials" book to their offering. Pluripotent stem cells have garnered tremendous interest in recent years, which is primarily driven by the hope of finding a cure for several debilitating human diseases. Cell transplantation (regeneratve medicine) offers considerable therapeutic potential. The procedure employs pluripotent stem cells as these have the inherent ability to reproduce indefinitely and have the ability to produce over 200 different types of cells constituting the human body. The isolation of human embryonic stem cells (hESCs) from embryos and their successful culture in a petri dish in 1998 has been considered as a major breakthrough that is set to shape stem cell research in the 21st century. This has been followed by another remarkable breakthrough in 2006 when scientists demonstrated for the first time that such pluripotent stem cells could be produced from adult somatic tissues without having to use human embryos. These pluripotent stem cells are called the induced pluripotent stem (iPS) cells. Both hESCs and iPS cells - highly versatile cells - could pave the way for alleviating patients suffering from diabetes, Parkinson's disease, Alzheimer's … Continue reading →